A late-stage trial testing Novartis’ Cosentyx in individuals with giant cell arteritis failed to meet its primary endpoint.  The phase 3 study tested Cosentyx alongside a 26-week steroid taper and compared it with a placebo along with a longer, 52-week…

The sweeping One Big Beautiful Bill Act, signed into federal law July 4, amended CMS’ drug price negotiations authority that could absolve nearly $5 billion in projected savings, according to the Congressional Budget Office.  CMS gained the authority to negotiate…

A new study suggests that the introduction of a real-time prescription benefit tool did not lead to meaningful changes in prescription spending or medication use among Medicare Advantage beneficiaries during its first year of implementation.  The analysis, published in JAMA…

A 79-year-old man with recurrent oropharyngeal cancer has developed the first documented case of severe drug-induced interstitial lung disease following photoimmunotherapy with cetuximab-sarotalocan sodium, according to a July 5 case report published in Science Direct.  Here are four notes: 

A new study projects that aligning U.S. cholesterol treatment with clinical guidelines could significantly reduce cardiovascular events nationwide.  The study, led by researchers at Baltimore-based Johns Hopkins University and Merck and published June 30 in the Journal of General Internal…

Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least four prior therapies, the agency said July 2.  The approval is based on…

Children’s National Hospital, based in Washington, D.C., earned accreditation for its specialty pharmacy services from URAC, an independent accreditor that sets national standards for quality and patient safety.  This marks the second URAC accreditation for Children’s National, which previously received…

Here are six new drug shortages and discontinuations, according to drug supply databases from the FDA. 

The battle over pharmacy benefit manager regulation is intensifying across the U.S. With the Supreme Court declining to revisit a key PBM case and Illinois signing sweeping new restrictions into law, PBM oversight remains a complex and evolving issue.  Here…

Health systems are rethinking how they structure and support their pharmacy teams, and the results are showing. Across the country, pharmacy leaders are implementing workforce changes to improve care delivery and drive greater operational efficiency.  Here are responses from three…